Yuyu Pharma

KSC:000220 · KR7000220004

PharmaceuticalsSmall

360

Medium confidence — indicative

Value55

Profit price9

Cash yield37

Owner Earnings Yield72

Dividend Yield1

Sales & asset price81

Price/Sales85

EV / Gross Profit76

Price/Book82

Quality66

Returns on capital80

Return on Capital88

Cash Return on Capital75

Return on Equity77

Profit margins73

EBIT Margin85

Gross Profitability60

Cash backing54

Cash Conversion66

Accruals29

Owner Earnings Margin67

Growth60

Sales growth47

Profit growth55

Profit Growth46

Long-Term EPS Growth48

Owner Earnings Growth72

Reinvestment34

Price momentum21

Safety61

Debt load71

Debt serviceability95

Refinancing89

Debt Payback100

Liquidity52

Sentiment40

Analyst ratings—

Expectations trend—

Market mood5

Value Creation10/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Yuyu Pharma clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeKOSE

Employees41

Websiteyuyu.co.kr

ISINKR7000220004

Last UpdateApr 2, 2026

Indices

KOSPI (South Korea)

Themes

EndocrinologyNeurologyManufacturingMedicalPharmaceutical

Description

Analysis

Middle-of-the-road

Yuyu Pharma, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is attractive. The owner-earnings multiple stands at 14.3×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 10/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Yuyu Pharma with its peers

Australian Ethical Investment

ASX:AEF

CountryAustralia

IndustryCapital Markets

SizeSmall

Full Stock Analysis →

Toyo Suisan Kaisha

TYO:2875

CountryJapan

IndustryFood Products

SizeLarge

Full Stock Analysis →

EQT Holdings

ASX:EQT

CountryAustralia

IndustryCapital Markets

SizeSmall

Full Stock Analysis →

Holtek Semiconductor

TAI:6202

CountryTaiwan

IndustrySemiconductors & Semiconductor Equipment

SizeSmall

Full Stock Analysis →

WA1 Resources

ASX:WA1

CountryAustralia

IndustryMetals & Mining

SizeSmall

Full Stock Analysis →

Stic Investments

KSC:026890

—

CountrySouth Korea

IndustryCapital Markets

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →